DocMorris AG (ZRSEF) Q4 2025 Earnings Call Transcript

Revenue grew 11.1% in 2025 while adjusted EBITDA was -48% as the company says it met guidance. Rx sales rose 33.2%, non-Rx +7.1%, and digital services surged 110%, now accounting for >50% of the company's contribution margin. The AI Health Companion (beta launched Oct) is being adopted quickly (≈1 in 3 app users), and year-end liquidity was CHF 160m as management reiterates a path to breakeven and cash generation in 2026–27.

Analysis

The structural read-through is that this business is transitioning from a margin-compressed retail model to a software-enabled, high-margin services platform; the real lever is not top-line growth but take-rates and churning non-core fulfillment costs. If management can sustain >50% incremental contribution margin on digital services, every point of additional penetration drives outsized EBITDA uplift given fixed-cost leverage in logistics and marketing — meaning the stock is effectively a multiple play on service monetization over 12–36 months.

Second-order winners include automation and last-mile logistics providers (outsourced order fulfilment and cold-chain partners) as volumes concentrate; conversely regional brick-and-mortar pharmacies and short-cycle wholesalers face margin pressure and footprint rationalization. Regulatory or payer pushback is the clearest economic clamp: price-cap changes, prescription routing rules, or data-usage limits would compress the newly earned take-rates much faster than consumer habits unwind, creating a binary 6–18 month downside tail.

Consensus appears to under-price execution risk around monetizing AI features and retaining unit economics as customer acquisition costs normalize. A sensible scenario model is bifurcated: a base where service take-rates reach mid-teens industry levels within two years (high upside to EBITDA) and a downside where regulatory headwinds or commercial reversals reset take-rates to legacy levels, wiping out more than half the implied incremental valuation. Time the exposure to near-term operating cadence (next two quarters) and regulatory calendar (policy reviews over 6–18 months).

Key Decisions for Investors

• Long asymmetric call spread on DocMorris (ticker: ZRSEF) — buy 12-month at-the-money call, sell 12-month call ~35% out; entry on <=10% pullback from current levels. Rationale: caps premium while keeping meaningful upside if service monetization continues; risk = premium paid (use 25% stop on premium), upside ~2.5-3x if shares re-rate 30–50% within 12 months.
• Pair trade — long ZRSEF / short Galenica (ticker: GALE.SW) equal notional for 6–12 months. Rationale: capture dispersion between digitally-native margin expansion and incumbent retail/distribution pressure. Target: profit if spread widens by 40%; stop-loss if spread tightens by 20%. Expected payoff asymmetric: 2:1 skew in base-case scenario.
• Directional long on automation/logistics exposure (example: KUKA, ticker: KUKA.DE) sized 5–10% of net exposure for 12–24 months. Rationale: benefit from outsized volume re-routing into centralized fulfilment; target 30–50% upside if B2C Rx volumes scale materially. Risk: industrial cyclicality — trim on order-book weakness or if automation capex stalls.